ALMS Anticipate a positive readout from the Phase 2B LUMUS study in Q3 will support SLE as an additional indication for ALMS' envudeucitinib

ALMS Anticipate a positive readout from the Phase 2B LUMUS study in Q3 will support SLE as an additional indication for ALMS' envudeucitinib @ OPCO